Ixazomib, Lenalidomide, and Dexamethasone (IRD) Treatment with Cytogenetic Risk-Based Maintenance in Transplant-Eligible Myeloma: A Phase 2 Multicenter Study by the Nordic Myeloma Study Group
Article in Cancers (February 2024)
The most recent citing publications are shown below. View all 13 publications that cite this research output on Dimensions.
Mobilization Strategies in Myeloma Patients Intended for Autologous Hematopoietic Cell Transplantation
Article in Transfusion Medicine and Hemotherapy (August 2023)
Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma
Article in Haematologica (August 2023)